Phase I Drug Trial for S/E of Marimastat in Disabling Malformations When no Other Options.

Summary

3 patients were enrolled in each of 3 study cohorts. There three cohorts were given differing, incrementally larger doses of this phase I drug. The same safety measures are being obtained on all patients. Efficacy measures were individualized as enrolllees do not have the same underlying vascular anomaly. The study is structured to include a 24 month drug-phase and a 24 month follow-up phase. The study is now closed to enrollment.

Timeline

Start

2000-10

Primary completion

—

Completion

2007-10

Drugs

Indications